Nada Yartey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nada Yartey has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Sean Platton
The Royal London Hospital Haemophilia Centre, Barts Health NHS Trust, London, UK
3 shared publications - Danielle White
Specialist Haemostasis Laboratory, Cambridge University Hospitals National Health Service Trust, Cambridge, UK
2 shared publications - Eleanor Foxton
Department of Diagnostic Haemostasis and Thrombosis, Synnovis Analytics, St Thomas' Hospital, London, UK
2 shared publications - Gary William Moore
Research and Development, Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH
2 shared publications - Stephen MacDonald
Specialist Haemostasis, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
2 shared publications - Annette Bowyer
Department of Coagulation Royal Hallamshire Hospital Sheffield UK
1 shared publication
Latest Publications
- 6 June 2024
- Published by Wiley in Haemophilia
- Vol. 30 (5) , 1221-1224
Evaluation of one‐stage and chromogenic assays for the laboratory measurement of factor VIII activity following valoctocogene roxaparvovec infusion
- 6 June 2024
- Published by Wiley in Haemophilia
- Vol. 30 (5) , 1221-1224
Evaluation of one‐stage and chromogenic assays for the laboratory measurement of factor VIII activity following valoctocogene roxaparvovec infusion
- 1 February 2024
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 46 (3) , 538-545
Taipan snake venom time has high sensitivity for lupus anticoagulants in non‐anticoagulated, triple positive antiphospholipid syndrome patients
Introduction: Dilute Russell's viper venom time (dRVVT) and activated partial thromboplastin time (APTT) are the mainstay assays in lupus anticoagulant (LA) detection yet they have limitations, particularly in relation to interferences and specificity. The recently validated Taipan snake venom time (TSVT) screening with ecarin time (ET) confirmatory assays overcome many of those limitations due to the innate specificity engendered from direct prothrombin activation, and insensitivity to the effects of vitamin K antagonists (VKA). The present study aimed to further evidence diagnostic utility of TSVT/ET by performing them in samples from 116 nonanticoagulated patients with established triple‐positive antiphospholipid syndrome (APS).Methods: Samples were identified in three expert centres who performed dRVVT, APTT and solid phase antiphospholipid antibody assays with reagents from a variety of manufacturers. All samples additionally received TSVT/ET analysis using standardised reagents.Results: Ninety seven of 116 (83.6%) were dRVVT‐ and APTT‐positive, 85/97 (87.6%) of which were TSVT/ET‐positive, 9/116 (7.8%) were dRVVT‐positive only, 6 of which were TSVT/ET‐positive, and 10/116 (8.6%) were APTT‐positive only, 5 of which were TSVT/ET‐positive. 96/116 TSVT/ET‐positivity returned a high sensitivity for LA of 82.8%. Low coefficients of determination revealed weak relationships between LA potency and anticardiolipin and anti‐β2‐glycoprotein I antibody titres for all three LA assays.Conclusions: TSVT/ET has high sensitivity for the clinically significant LA found in triple positive APS patients. TSVT/ET can establish multiple LA assay positivity in nonanticoagulated patients negative for one of dRVVT or APTT, and is the only assay pairing insensitive to VKAs, the recommended anticoagulation for APS.
- 1 February 2024
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 46 (3) , 538-545
Taipan snake venom time has high sensitivity for lupus anticoagulants in non‐anticoagulated, triple positive antiphospholipid syndrome patients
Introduction: Dilute Russell's viper venom time (dRVVT) and activated partial thromboplastin time (APTT) are the mainstay assays in lupus anticoagulant (LA) detection yet they have limitations, particularly in relation to interferences and specificity. The recently validated Taipan snake venom time (TSVT) screening with ecarin time (ET) confirmatory assays overcome many of those limitations due to the innate specificity engendered from direct prothrombin activation, and insensitivity to the effects of vitamin K antagonists (VKA). The present study aimed to further evidence diagnostic utility of TSVT/ET by performing them in samples from 116 nonanticoagulated patients with established triple‐positive antiphospholipid syndrome (APS).Methods: Samples were identified in three expert centres who performed dRVVT, APTT and solid phase antiphospholipid antibody assays with reagents from a variety of manufacturers. All samples additionally received TSVT/ET analysis using standardised reagents.Results: Ninety seven of 116 (83.6%) were dRVVT‐ and APTT‐positive, 85/97 (87.6%) of which were TSVT/ET‐positive, 9/116 (7.8%) were dRVVT‐positive only, 6 of which were TSVT/ET‐positive, and 10/116 (8.6%) were APTT‐positive only, 5 of which were TSVT/ET‐positive. 96/116 TSVT/ET‐positivity returned a high sensitivity for LA of 82.8%. Low coefficients of determination revealed weak relationships between LA potency and anticardiolipin and anti‐β2‐glycoprotein I antibody titres for all three LA assays.Conclusions: TSVT/ET has high sensitivity for the clinically significant LA found in triple positive APS patients. TSVT/ET can establish multiple LA assay positivity in nonanticoagulated patients negative for one of dRVVT or APTT, and is the only assay pairing insensitive to VKAs, the recommended anticoagulation for APS.
- 18 August 2023
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 21 (12) , 3539-3546
Triple-positive antiphospholipid syndrome does not guarantee positivity in each lupus anticoagulant assay
- 18 August 2023
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 21 (12) , 3539-3546
Triple-positive antiphospholipid syndrome does not guarantee positivity in each lupus anticoagulant assay